Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Rivaroxaban Tablet vs Granule in Healthy Japanese Men
NCT02537405Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in embolism, Atrial fibrillation (AFib) and venous thrombosis (2 arms), sponsored by Bayer. Primary endpoints: Maximum Observed Drug Concentration up to 3 days and Area Under the Concentration-Time Curve from Time 0 to Last Quantifiable Concentration up to 3 days. Started Feb 2014; status: completed.
02
Drugs
rivaroxaban
03
Conditions
embolismAtrial fibrillation (AFib)venous thrombosis
Beyond the preview
Go deeper on NCT02537405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537405.